Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. WO2022007903 - COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF

Publication Number WO/2022/007903
Publication Date 13.01.2022
International Application No. PCT/CN2021/105275
International Filing Date 08.07.2021
IPC
C07D 401/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 417/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14containing three or more hetero rings
C07D 471/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 471/08 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
08Bridged systems
C07D 471/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
10Spiro-condensed systems
A61K 31/444 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
444containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
Applicants
  • 四川海思科制药有限公司 SICHUAN HAISCO PHARMACEUTICAL CO., LTD. [CN]/[CN]
Inventors
  • 张晨 ZHANG, Chen
  • 廖雨亭 LIAO, Yuting
  • 祝国智 ZHU, Guozhi
  • 叶飞 YE, Fei
  • 程新帆 CHENG, Xinfan
  • 陈孝刚 CHEN, Xiaogang
  • 唐平明 TANG, Pingming
  • 李瑶 LI, Yao
  • 倪佳 NI, Jia
  • 严庞科 YAN, Pangke
Agents
  • 北京三友知识产权代理有限公司 BEIJING SANYOU INTELLECTUAL PROPERTY AGENCY LTD.
Priority Data
202010655931.009.07.2020CN
202010776540.407.08.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF
(FR) COMPOSÉ CAPABLE D'INHIBER ET DE DÉGRADER LES RÉCEPTEURS AUX ANDROGÈNES ET COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS PHARMACEUTIQUES
(ZH) 一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用
Abstract
(EN) A compound as shown in general formula B-L-K (I) or stereoisomers, deuterated compounds, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or co-crystals thereof, and intermediates thereof and uses thereof for AR-related diseases such as prostate cancer.
(FR) L'invention concerne un composé tel que présenté dans la formule générale B-L-K (I) ou des stéréoisomères, des composés deutérés, des solvates, des promédicaments, des métabolites, des sels pharmaceutiquement acceptables ou des cocristaux de ceux-ci, et des intermédiaires de ceux-ci et leurs utilisations pour des maladies associées aux RA telles que le cancer de la prostate.
(ZH) 提供了一种通式B-L-K (I)所述的化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶,及其中间体,以及在AR相关疾病如前列腺癌中的用途。
Latest bibliographic data on file with the International Bureau